Eli Lilly gets nod to sell weight-loss drug in Hong Kong by year-end - report

jetcityimage/iStock Editorial via Getty Images Eli Lilly ( NYSE: LLY ) received approval from the Hong Kong government to launch its weight-loss drug—Mounjaro, with sales expected to begin as early as year-end, Bloomberg reported. The company got approval to sell its tirzepatide injections—branded as Mounjaro—in a device called Kwikpen. Mounjaro is.